Published 2017
| Version v1
Journal article
FDG PET-CT: Need for Vigilance in Patients Treated with Bleomycin
- 1. Theagenion Cancer Hospital, Thessaloniki (Greece)
- 2. Royal Free London NHS Foundation Trust, London (United Kingdom)
- 3. KCL Division of Imaging Sciences & Biomedical Engineering, London (United Kingdom)
Description
Bleomycin-induced interstitial lung disease is not a rare complication of treatment and may prove to be fatal if not suspected early in its course. As FDG PET-CT has become an essential clinical tool for interim and end-of-treatment response assessment in oncology, it is important that radiologists/nuclear medicine specialists be aware of the features of this potentially treatable condition so that treatment can be instigated during an early reversible phase before pulmonary damage has occurred. Herein, we report two cases of bleomycin toxicity featuring different patterns on the treatment-response assessment FDG PET-CT scan.
Availability note (English)
Available from http://dx.doi.org/10.4103/0972-3919.202242; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439189Additional details
Identifiers
Publishing Information
- Journal Title
- Indian Journal of Nuclear Medicine
- Journal Volume
- 32
- Journal Issue
- 2
- Journal Page Range
- p. 122-124
- ISSN
- 0972-3919
INIS
- Country of Publication
- India
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49087845
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BLEOMYCIN; NUCLEAR MEDICINE; POSITRON COMPUTED TOMOGRAPHY
- Descriptors DEC
- ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTIMITOTIC DRUGS; ANTINEOPLASTIC DRUGS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; MEDICINE; ORGANIC COMPOUNDS; TOMOGRAPHY
Optional Information
- Notes
- PMCID: PMC5439189; PMID: 28533640; PUBLISHER-ID: IJNM-32-122; OAI: oai:pubmedcentral.nih.gov:5439189; Copyright: (c) 2017 Indian Journal of Nuclear Medicine